In the high-stakes world of biotech investing, few stocks have captured attention like Bio-Path Holdings (BPTH) in recent trading sessions. Valued at a market cap of $5.8 million, BPTH stock almost tripled in a single trading session last week as speculative investors hunted for the next big thing.
Bio-Path has a proprietary drug delivery platform called DNAbilize and a pipeline that targets aggressive blood cancers. While the dust is yet to settle on the company’s recent uptick in valuation, investors face a critical question: Does this tiny Texas-based company offer genuine value, or is the recent rally merely speculative froth in a notoriously volatile sector?
